Core Viewpoint - Baijia Pharmaceutical-B (02659) has seen its stock price increase by over 440% from its IPO price of 26.38 HKD, reaching a high of 143 HKD, indicating strong market interest and potential growth in its product pipeline [1] Company Overview - Baijia Pharmaceutical has developed China's first marketed recombinant hyaluronidase KJ017 for large-volume subcutaneous administration [1] - The company also has the world's first IgG degrading enzyme KJ103, which shows "best-in-class" potential in low pre-storage antibody and administration frequency, targeting antibody-mediated autoimmune diseases [1] - Additionally, Baijia has a long-acting follicle-stimulating hormone drug SJ02, which has been validated through collaboration and is aimed at assisted reproduction [1] Commercialization Progress - The three core products have entered commercialization, new drug application registration, or late-stage clinical trials in China, indicating a transition from pure R&D to commercialization for Baijia Pharmaceutical [1] - According to a report from Xiniu Securities, Baijia has established a clear commercialization model and timeline, with expectations for significant revenue contributions starting in 2026 from KJ017 and SJ02 [1] - KJ103, which is applied in kidney transplant desensitization, is anticipated to start contributing to revenue in 2027, with further applications for GBS and anti-GBM diseases expected to follow at a later date [1]
港股异动 | 宝济药业-B(02659)再涨超10% 较招股价已涨近4.5倍 多款产品今年起将显著贡献收入